SAN FRANCISCO Feb. 17, 2011
"It is gratifying to see DecisionView succeeding and gaining traction in the pharmaceutical industry," said Alex Lancksweert, Director of Performance & Supplier Governance at GlaxoSmithKline. "As an early adopter, we’ve worked with DecisionView over the years to promote a more robust approach to planning and tracking recruitment of clinical trials. The result has been increased visibility and predictability of patient enrollment."
In addition to strong growth in subscription licenses and contracted clinical trials, 2010 was a very strong year for DecisionView in a number of other areas as well. In 2010, the company:
- Increased penetration to 7 of the top 10 global pharmaceutical companies (up from 4 of the top 10)
- Launched StudyOptimizer 4.2, with innovative new features including historical analysis of enrollment performance, future cost forecasting, and integration with leading enterprise portals
- Drove significant customer adoption of the company’s new 4.x platform. The 3.x version of StudyOptimizer will be retired in first half of 2011 when total customer migration will be completed.
- Pfizer’s CIO 100 award
Jim Scullion Linda Drumright
SOURCE DecisionView Inc.